BeiGene Ltd (BGNE)
167.92
+0.53
(+0.32%)
USD |
NASDAQ |
May 22, 16:00
167.53
-0.39
(-0.23%)
After-Hours: 20:00
BeiGene Cash from Investing (Quarterly): -209.83M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -209.83M |
| December 31, 2023 | -62.58M |
| September 30, 2023 | -186.28M |
| June 30, 2023 | 67.80M |
| March 31, 2023 | 241.06M |
| December 31, 2022 | 38.54M |
| September 30, 2022 | 169.48M |
| June 30, 2022 | 658.71M |
| March 31, 2022 | 210.39M |
| December 31, 2021 | 109.11M |
| September 30, 2021 | -12.00M |
| June 30, 2021 | 251.60M |
| March 31, 2021 | 291.95M |
| December 31, 2020 | -86.92M |
| September 30, 2020 | -1.537B |
| June 30, 2020 | -429.90M |
| March 31, 2020 | -1.115B |
| December 31, 2019 | -23.89M |
| September 30, 2019 | 213.63M |
| Date | Value |
|---|---|
| June 30, 2019 | 192.01M |
| March 31, 2019 | 172.42M |
| December 31, 2018 | 213.24M |
| September 30, 2018 | -490.64M |
| June 30, 2018 | 34.13M |
| March 31, 2018 | -394.35M |
| December 31, 2017 | -68.24M |
| September 30, 2017 | -401.33M |
| June 30, 2017 | 69.71M |
| March 31, 2017 | 43.54M |
| December 31, 2016 | -170.72M |
| September 30, 2016 | 44.08M |
| June 30, 2016 | -135.55M |
| March 31, 2016 | 40.34M |
| December 31, 2015 | 7.302M |
| September 30, 2015 | 6.254M |
| June 30, 2015 | -75.69M |
| March 31, 2015 | 3.231M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-1.537B
Minimum
Sep 2020
658.71M
Maximum
Jun 2022
-60.93M
Average
53.17M
Median
Cash from Investing (Quarterly) Benchmarks
| Theravance Biopharma Inc | 17.03M |
| LumiraDx Ltd | -0.821M |
| Dr Reddy's Laboratories Ltd | -139.12M |
| ASLAN Pharmaceuticals Ltd | -- |
| Jazz Pharmaceuticals PLC | -271.90M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -308.57M |
| Cash from Financing (Quarterly) | 162.29M |
| Free Cash Flow | -1.566B |
| Free Cash Flow Per Share (Quarterly) | -4.811 |
| Free Cash Flow to Equity (Quarterly) | -641.63M |
| Free Cash Flow to Firm (Quarterly) | -501.62M |
| Free Cash Flow Yield | -8.88% |